| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.039 | 0.8 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.8 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.017 | 0.8 |
| mRNA | Bosutinib | FIMM | pan-cancer | AAC | -0.076 | 0.8 |
| mRNA | vorinostat:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.8 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.8 |